IQVIA (NYSE:IQV) Upgraded by StockNews.com to “Buy” Rating

StockNews.com upgraded shares of IQVIA (NYSE:IQV) from a hold rating to a buy rating in a report published on Wednesday.

IQV has been the topic of several other reports. JPMorgan Chase & Co. lowered their price target on shares of IQVIA from $288.00 to $279.00 and set an “overweight” rating on the stock in a report on Wednesday, October 23rd. Truist Financial lowered their target price on IQVIA from $300.00 to $286.00 and set a “buy” rating on the stock in a research note on Monday, October 14th. Argus upgraded IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. Jefferies Financial Group lowered IQVIA from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $266.00 to $242.00 in a research report on Wednesday, July 24th. Finally, Morgan Stanley lifted their target price on shares of IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, July 23rd. Four equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and an average target price of $261.24.

IQVIA Stock Up 1.6 %

IQV stock opened at $209.16 on Wednesday. The company has a market capitalization of $38.13 billion, a P/E ratio of 27.45, a price-to-earnings-growth ratio of 2.01 and a beta of 1.51. IQVIA has a 12 month low of $181.03 and a 12 month high of $261.73. The firm’s fifty day simple moving average is $234.31 and its 200-day simple moving average is $229.74. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.85.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On IQVIA

A number of hedge funds have recently modified their holdings of IQV. 1832 Asset Management L.P. grew its stake in IQVIA by 472.3% during the 2nd quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock valued at $96,487,000 after acquiring an additional 376,595 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of IQVIA in the second quarter valued at approximately $70,610,000. Impax Asset Management Group plc lifted its position in IQVIA by 19.3% during the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock worth $344,998,000 after buying an additional 264,555 shares in the last quarter. Canada Pension Plan Investment Board boosted its stake in IQVIA by 6.6% during the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock worth $719,634,000 after buying an additional 211,653 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. grew its holdings in IQVIA by 285.1% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 268,552 shares of the medical research company’s stock valued at $56,783,000 after buying an additional 198,808 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.